RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer

FORT WASHINGTON, Pennsylvania, Nov. 13, 2012 /PRNewswire/ -- ReSearch Pharmaceutical Services, Inc. (RPS), a next generation CRO that provides comprehensive global Phase 1-4 clinical development solutions to the biopharmaceutical and medical device industries, today announced that Jonathan M. Fishbein, M.D. has joined the organization as Executive Vice President and Chief Medical Officer.

In his role, he will have the responsibility of providing leadership and strategic direction to the Medical, Safety, and Medical Writing departments. Dr. Fishbein has extensive experience in the planning and execution of clinical research in a broad range of therapeutic areas.

Dr. Fishbein joins RPS having recently served as a Vice President in several medical and scientific capacities at ICON Clinical Research.

Dr. Fishbein has over 20 years experience in clinical and basic research, working in the CRO industry, as well as the Government, academic and non-profit sectors. Before joining ICON, he simultaneously held the positions of Special Assistant to the Deputy Director of the National institute of Allergy and Infectious Diseases (NIAID) and Senior Fellow at the International Center for Research on Women. Prior to those positions, he served as the first Director of the Office for Policy in Clinical Research Operations (OPCRO) at the NIAID's Division of AIDS. In that role, Dr. Fishbein enforced compliance with regulations, guidance and policies to assure that federally-funded clinical research in HIV/AIDS met established standards of quality, integrity and ethics to protect the safety, rights, and confidentiality of human research subjects.

Before government service, he held various roles at PAREXEL International Corporation, including Vice President of North American Medical Services.

A surgeon by training, Dr. Fishbein was a Medical Staff Fellow at the National Cancer Institute (Immunology Branch) and a Fellow in Transplantation Immunology at the Transplantation Biology Research Center at the Massachusetts General Hospital/Harvard Medical School.

"Jonathan brings significant expertise to RPS, and we are extremely pleased to welcome him as a member of our Executive Management Team. His addition builds on the depth and breadth of our strategic medical affairs leadership, and allows RPS to continue the growth of our global drug safety organization," said Alan Morgan, Chief Operating Officer.

About RPS

RPS provides comprehensive global Phase I-IV clinical development solutions to the Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries. By combining our highly experienced clinical research operations infrastructure with the industry's largest resourcing engines, RPS is uniquely positioned to offer our Customers a broad spectrum of outsourcing solutions. These solutions range from globally Embedded functional and cross-functional programs to enhanced global full-service solutions, and are powered by highly experienced project teams providing innovative, seamless, cost-effective and high quality services.

With more than 5,000 employees, RPS operates in more than 64 countries across the globe.